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Abstract
Background: Screening of primary care patients at risk for left ventricular systolic dysfunction by
a simple blood-test might reduce referral rates for echocardiography. Whether or not natriuretic
peptide testing is a useful and cost-effective diagnostic instrument in primary care settings,
however, is still a matter of debate.
Methods: N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, clinical information, and
echocardiographic data of left ventricular systolic function were collected in 542 family practice
patients with at least one cardiovascular risk factor. We determined the diagnostic power of the
NT-proBNP assessment in ruling out left ventricular systolic dysfunction and compared it to a risk
score derived from a logistic regression model of easily acquired clinical information.
Results: 23 of 542 patients showed left ventricular systolic dysfunction. Both NT-proBNP and the
clinical risk score consisting of dyspnea at exertion and ankle swelling, coronary artery disease and
diuretic treatment showed excellent diagnostic power for ruling out left ventricular systolic
dysfunction. AUC of NT-proBNP was 0.83 (95% CI, 0.75 to 0.92) with a sensitivity of 0.91 (95%
CI, 0.71 to 0.98) and a specificity of 0.46 (95% CI, 0.41 to 0.50). AUC of the clinical risk score was
0.85 (95% CI, 0.79 to 0.91) with a sensitivity of 0.91 (95% CI, 0.71 to 0.98) and a specificity of 0.64
(95% CI, 0.59 to 0.67). 148 misclassifications using NT-proBNP and 55 using the clinical risk score
revealed a significant difference (McNemar test; p < 0.001) that was based on the higher specificity
of the clinical risk score.
Conclusion: The evaluation of clinical information is at least as effective as NT-proBNP testing in
ruling out left ventricular systolic dysfunction in family practice patients at risk. If these results are
confirmed in larger cohorts and in different samples, family physicians should be encouraged to rely
on the diagnostic power of the clinical information from their patients.
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Background
Early detection of left ventricular systolic dysfunction is
important, since early treatment with ACE inhibitors has
been shown to delay the progression toward overt conges-
tive heart failure (CHF) and to prolong life [1]. Since diag-
nosis of left ventricular systolic dysfunction solely based
on clinical symptoms may be difficult [2], echocardiogra-
phy is recommended as the diagnostic gold standard [3].
However, access to echocardiography in a primary care
setting is limited, as the European survey of primary care
physician perceptions on heart failure diagnosis and man-
agement (EURO-HF) showed [4].
To date, general practitioners have to identify patients in
need of a referral to echocardiography by clinical informa-
tion, which is routinely obtained from medical history
and physical examination. Eventually, a pre-selection of
patients at risk could reduce referral rates for echocardiog-
raphy [3]. Therefore, a screening test (such as blood natri-
uretic peptide concentrations) which could easily be
administered in primary care and reliably rule out left ven-
tricular systolic dysfunction would reduce referral rates for
echocardiography and lower health care costs. A retro-
spective analysis of cost-effectiveness showed that brain
natriuretic peptide (BNP) testing could have reduced the
costs per detected case by 26% compared to echocardiog-
raphy [5].
Recent studies showed that the assessment of patients at
high risk for left ventricular systolic dysfunction by means
of N-terminal pro-brain natriuretic peptide (NT-proBNP)
assays was valuable in the diagnosis of left ventricular
systolic dysfunction [6,7] and heart failure [8]. However,
there are conflicting results as to the usefulness of natriu-
retic peptides in identifying left ventricular systolic dys-
function after myocardial infarction [9]. Thus, ruling out
left ventricular systolic dysfunction in primary care
patients at risk by NT-proBNP is still a matter of debate.
Additionally, the question whether NT-proBNP is diag-
nostically more suitable than easily available clinical
information (as used today) has not yet been examined.
We therefore investigated the diagnostic ability of NT-
proBNP testing compared to a risk score derived from a
logistic regression model of easily acquired clinical infor-
mation to detect left ventricular systolic dysfunction in
primary care patients at risk.
Methods
Study Population
Between January 2003 and June 2004, 2,273 primary care
patients from 58 practices in the city of Göttingen (North
Germany) and the surrounding communities were invited
by their general practitioners to participate in the study.
Inclusion criteria were the presence of at least one cardio-
vascular risk factor documented by the family physician,
including arterial hypertension, diabetes, family history of
early heart disease, and coronary artery disease. Patients
were classified as hypertensive if hypertension was docu-
mented by their treating physician or if they were on anti-
hypertensive therapy. Patients were classified as diabetic if
this diagnosis was made by their treating physician or if
they were on antihyperglycemic therapy.
Exclusion criteria were the diagnosis of heart failure docu-
mented by the family physician or the presence of a termi-
nal or disabling chronic disease. Patients received a leaflet
with general information about the purpose of the study
and how to participate. A total of 542 patients agreed to
participate and were examined at the Georg-August-Uni-
versity, department of cardiology. Patients were inter-
viewed, clinically examined, and assessed by
echocardiography. Fifteen ml of blood were taken from a
forearm vein for the measurement of NT-proBNP level.
Determination of N-terminal brain natriuretic peptide
Before the study appointment, patients completed an
overnight fast except for taking their regularly prescribed
medications. A 21-gauge butterfly needle was inserted
intravenously in the forearm, and after a 30-minute
supine rest, blood samples were drawn into lithium-
heparinate tubes; these were centrifugated and the super-
natant was divided into aliquots and stored at minus
70°C. We used the Elecsys® assay (Roche Diagnostics,
Mannheim, Germany) to measure NT-proBNP in
defrosted samples. The lowest detectable measurement
for this assay was 5 pg/mL. The interassay coefficient of
variation was 2.7% for 175 pg/mL, 2.7% for 355 pg/mL,
1.9% for 1068 pg/mL and 1.8% for 4962 pg/ml. The lab-
oratory technician who measured NT-proBNP levels was
at a different site and blinded to the characteristics of the
patients and the results of echocardiograms. NT-proBNP
reagents were kindly provided by Roche Diagnostics (Pro-
fessor G. Hess, Mannheim, Germany).
Echocardiographic measurements
Echocardiograms were performed with a Phillips Ultra-
sound System (Phillips Sonos Agilent) using a 3.5-MHz
transducer with the patient in the left lateral position. A
complete resting 2D echocardiogram and Doppler ultra-
sound examination was performed. We obtained stand-
ard 2D parasternal long and short-axis to determine left
ventricular dimensions. We calculated left ventricular
ejection fraction (EF) by the quantitative 2-D (biplane
Simpson) method. An EF<50% was defined as systolic
ventricular dysfunction. Echocardiograms were addition-
ally rated concerning abnormalities defined as diastolic
dysfunction [10]. Three of the authors (CL, SK, RW) inter-
preted all echocardiograms and were blinded to theBMC Family Practice 2008, 9:14 http://www.biomedcentral.com/1471-2296/9/14
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results of the NT-proBNP assay as well as to details of the
medical history.
Statistical analysis
Assessing group differences, we used t-tests for continuous
variables and Chi-Square-tests for comparisons of fre-
quencies. A multiple logistic regression analysis was done
to identify clinical variables that have a statistically signif-
icant diagnostic value in predicting left ventricular systolic
dysfunction. We used a backward conditional model,
including sociodemographic and clinical variables.
Selected variables were used to estimate an individual
patient risk score, thus, the sum of the β coefficients for
each of the specific risk factors multiplied by their actual
values [11].
We assessed the diagnostic performance of the NT-
proBNP assay and the risk score by using receiver operat-
ing characteristic curves (ROC). The overall discriminative
power of NT-proBNP and the clinical risk score is shown
by the area under the curve (AUC). Comparisons between
AUCs were assessed according to the method of Hanley &
McNeil [12]. In addition to the AUC, we compared the
test accuracy of NT-proBNP and the clinical risk score
using the McNemar test (i.e. comparison of discordant
pairs of false classifications). We chose cut-off points that
gave comparable high sensitivity levels and moderate (at
least 40%) specificity levels in order to optimize the neg-
ative predictive power of the test (SnNout; very high sen-
sitivity: negative result rules out the diagnosis/disease)
[13,14].
All analyses were two-tailed and the alpha was defined at
0.05. Statistical analyses were carried out using SPSS and
Microsoft EXCEL. The study was approved by the local
ethics committee, and all patients gave written informed
consent before examination.
Results
Left ventricular function in patients at high risk for heart 
failure
Table 1 shows the sociodemographic and clinical charac-
teristics of the 542 patients. In 23 patients (4%), EF was
below 50%. These patients were significantly older, and
complained significantly more often about dyspnea and
ankle swelling than those with an EF ≥ 50%. Patients with
Table 1: Demographic and clinical characteristics, and drug treatment of patients with preserved and with impaired left ventricular 
systolic function.
Variables† Patients with preserved systolic function (n = 519) Patients with impaired systolic function (n = 23) P*
Patient characteristics
Age, years, 63 (62 to 63) 69 (66 to 73) 0.003
Male, % 57 70 0.241
BMI 29 (29 to 30) 29 (27 to 31) 0.854
Systolic BP, mm Hg 151 (149 to 152) 146 (138 to 155) 0.342
Diastolic BP, mm Hg 86 (85 to 86) 83 (78 to 89) 0.361
Ejection Fraction, % 61 (60 to 62) 41 (38 to 45) <0.001
NT-proBNP, pg/ml 218 (174 to 259) 1154 (236 to 2072) <0.001
Symptoms
Dyspnea at exertion, % 34 74 <0.001
Dyspnea at rest, % 1 9 0.003
Ankle swelling, % 33 74 <0.001
Medical history
Diabetes, % 31 39 0.400
Hypertension, % 86 96 0.184
Hyperlipidemia, % 51 74 0.032
CAD, % 29 65 <0.001
Myocardial infarction, % 7 22 0.019
Fam. history heart disease, % 42 57 0.168
Drug treatment
Diuretics, % 42 74 0.003
β blockers, % 57 74 0.105
Calcium channel blockers, % 23 22 0.928
ACE inhibitors, % 46 52 0.564
AT1 blockers, % 16 26 0.201
Lipid lowerings agents, % 35 74 <0.001
* T-Test or χ2-Test.
† values in mean (95% confidence interval) unless otherwise indicated.
BMI Body Mass Index; BP blood pressure; CAD coronary artery disease; ACE angiotension converting enzyme, AT1 blocker angiotensin II type 1 
receptor blocker.BMC Family Practice 2008, 9:14 http://www.biomedcentral.com/1471-2296/9/14
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a reduced EF also reported more often a history of myo-
cardial infarction, coronary artery disease, and hyperlipi-
demia, and more often took diuretics and lipid-lowering
agents. Levels of NT-proBNP were significantly higher in
patients with systolic dysfunction when compared to
patients with preserved left ventricular function. Three
hundred and ninety nine patients of those without systo-
lic dysfunction showed signs of diastolic dysfunction; in
most cases (83%) of the lowest grade, i.e. impaired relax-
ation.
Relationship of left ventricular systolic dysfunction with 
sociodemographic and clinical variables
A logistic stepwise regression with left ventricular dysfunc-
tion as the dependent variable and 17 independent varia-
bles as covariates was conducted. The backward
conditional model selected the following three covariates:
dyspnea at exertion combined with ankle swelling, history
of coronary artery disease, and treatment with diuretics.
Other variables were entered into the model but were
excluded by the stepwise regression: age (dichotomized
by the median), sex, BMI>30, diabetes mellitus, hyperten-
sion, hyperlipidemia, myocardial infarction, family his-
tory of early heart disease, treatment with ACE inhibitors,
β blockers, calcium channel blockers, AT1 blockers, or
lipid lowering agents (Table 2).
Diagnoses of left ventricular systolic dysfunction based on 
NT-proBNP levels or clinical information
Figure 1a shows the AUC for NT-proBNP. This illustrates
its diagnostic value for left ventricular systolic dysfunc-
tion, which can be rated as excellent. The cut-off point of
NT-proBNP was determined as having a moderate specif-
icity and a high sensitivity compared to the clinical risk
score. Concentrations below the cut-off point allowed for
the exclusion of left ventricular systolic dysfunction. The
negative likelihood ratio of a NT-proBNP value below
98.5 pg/ml is 0.19. It indicates that the probability of a
negative test result is five times lower in patients with
impaired left ventricular systolic dysfunction than in
patients with preserved left ventricular function. Table 3
shows the cut-off point dependent measures of NT-
proBNP as a diagnostic test.
Figure 1b shows the AUC for the clinical risk score includ-
ing the following variables: suffering from ankle swelling
and dyspnea at exertion, history of coronary artery dis-
ease, and treatment with diuretics. The backward condi-
tional model with left ventricular dysfunction as the
dependent variable selected these risk factors (Table 2). To
obtain the individual patient risk score, the β coefficients
for each of the specific risk factors were multiplied by their
actual values and then summed up. For example, individ-
ual patient risk score = (β1 × dyspnea at exertion × ankle
swelling) + (β2 × coronary artery disease) + (β3 × diuret-
ics). AUC of the clinical risk score indicates its diagnostic
value for left ventricular systolic dysfunction and can be
rated as excellent.
The cut-off point was determined as having a moderate
specificity and a high sensitivity compared to the NT-
proBNP test. The negative likelihood ratio of a clinical risk
score below 1.11 is 0.14 and indicates that the probability
of a negative test result is seven times lower in patients
with impaired left ventricular systolic dysfunction than in
patients with preserved left ventricular function. Table 3
shows the cut-off point dependent measures for the clini-
cal risk score as a diagnostic test.
Comparison of NT-proBNP testing and the clinical risk 
score for identifying left ventricular systolic dysfunction
The minimal difference of 0.019 between AUCs of NT-
proBNP and the clinical risk score was not significant (Fig-
ure 1). Table 4 shows the number of correct and false clas-
sifications for both, the risk score and NT-proBNP as
single diagnostic tests. Comparing the two tests, there are
four different cases possible: Cases shown in the first line
and first row (n = 203) were correctly classified by both
tests, i.e. they are true positive and true negative diag-
noses. Cases shown in the second line and second row (n=
136) were falsely classified by both tests, i.e. they are false
positive and false negative diagnoses. Cases shown in the
first line and second row (n = 148) were falsely classified
by NT-proBNP but correctly classified by the risk score.
Cases shown in the second line and first row (n = 55) were
falsely classified by the risk score but correctly classified by
NT-proBNP. The McNemar test showed that this differ-
Table 2: Logistic regression analysis of demographic and clinical variables associated with left ventricular systolic dysfunction.*
Covariates Regression coefficient Odds ratio (95% CI)
Dyspnea at exertion + ankle swelling 1.819 6.165 (2.400 to 15.842)
Coronary artery disease 1.182 3.261 (1.282 to 8.293)
Diuretic treatment 1.035 2.814 (1.038 to 7.626)
*Presented covariates were selected by backward conditional model. Other variables entered into model were age>64 years, sex, BMI>30, diabetes 
mellitus, hypertension, hyperlipidemia, myocardial infarction; family history of early heart disease, dyspnea at rest, taking ACE inhibitors, β blockers, 
calcium channel blockers, AT1 blockers, lipid lowering agents.BMC Family Practice 2008, 9:14 http://www.biomedcentral.com/1471-2296/9/14
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ence concerning the discordant pairs of false classifica-
tions was significant. The advantage of using the clinical
risk score for classification was based on the better specif-
icity, resulting in a lower rate of false positive cases.
Discussion
To our knowledge, this study is the first to compare the
diagnostic power of NT-proBNP assessment and a risk
score derived from a logistic regression model of easily
acquired clinical information in a primary care setting.
Both, NT-proBNP testing and the clinical risk score relia-
bly ruled out left ventricular systolic dysfunction in a
cohort of 542 primary care patients at risk. This data con-
firmed the diagnostic value of NT-proBNP assessment in
ruling out left ventricular systolic dysfunction [15,16].
Although we aimed for a large number of patients to par-
ticipate in the study, only 542 of 2273 patients accepted
the invitation and could be included. Thus, our study has
some limitations. First, the sample size of our study is too
small to derive age and gender adjusted cut-off values that
might have improved the diagnostic accuracy of NT-
proBNP. Additionally, our logistic regression might have
reduced statistical evidence due to the high number of
independent variables. As we did not perform a hypothe-
sis testing regression analysis we assume that it was suita-
ble for development of our clinical risk score. Second, our
study may be biased to model a reliable and valid risk
equation and therefore it is necessary for further studies to
recalculate our clinical risk score equation in larger
cohorts and evaluate it in different samples [17]. Third, we
decided not to take the echocardiographic findings of
diastolic dysfunction into account for statistical analysis,
since there are divergent study findings concerning the
clinical implication of the diagnosis of diastolic dysfunc-
tion in primary care. Critical objections affect the lack of
Receiver-operator characteristic (ROC) curves for (a) NT-proBNP (AUC = 83%; 95 % CI = 75% to 92%) and (b) clinical risk  score (AUC = 85%; 95 % CI = 79% to 91%) in the diagnosis of left ventricular systolic dysfunction confirmed by echocardiogra- phy in patients with preserved (n = 519) and impaired (n = 23) left ventricular function Figure 1
Receiver-operator characteristic (ROC) curves for (a) NT-proBNP (AUC = 83%; 95 % CI = 75% to 92%) and (b) 
clinical risk score (AUC = 85%; 95 % CI = 79% to 91%) in the diagnosis of left ventricular systolic dysfunction 
confirmed by echocardiography in patients with preserved (n = 519) and impaired (n = 23) left ventricular 
function.









Sensitivity (%) Specificity (%) Likelihood ratio of negative result 
(95% CI)
NT-proBNP (< 98.5 pg/ml) 21 282 2 237 91 (71 to 98) 46 (41 to 50) 0.19 (0.05 to 0.71)
Risk score (< 1.11) 21 189 2 330 91 (71 to 98) 64 (59 to 67) 0.14 (0.04 to 0.51)
*At cut-off points with comparable high sensitivity and moderate specificity in order to rule out left ventricular dysfunction in case of a negative 
result (SnNout; very high sensitivity: negative result rules out the diagnosis/disease. Values in parentheses are 95% confidence intervals.BMC Family Practice 2008, 9:14 http://www.biomedcentral.com/1471-2296/9/14
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evidence based treatment [18] and poor concordance of
echocardiographic measures [19]. Fourth, our study
might have been further improved by using an electrocar-
diography as an additional diagnostic tool since its useful-
ness in detecting left ventricular systolic dysfunction has
been suggested [20,21]. However, due to a recent meta-
analysis electrocardiography may not be used for ruling
out left ventricular hypertrophy in patients with hyperten-
sion [22].
We used a logistic regression analysis to model the risk
score including demographic and clinical variables. Inde-
pendent factors significantly associated with systolic dys-
function were suffering from dyspnea at exertion and
ankle swelling, a history of coronary artery disease, and
taking diuretics. In a comparable study of 764 primary
care patients, Raymond et al. conducted a logistic regres-
sion analysis and revealed male sex, admission for pulmo-
nary congestion and/or myocardial infarction, and
breathlessness as significant factors to predict left ven-
tricular systolic dysfunction [21]. Although our study
showed that history of myocardial infarction and pre-
scription of diuretics and lipid lowering agents was more
frequent in patients with impaired than with preserved
systolic function (see table 1), this variables were not
selected by the regression analysis. In contrast to Ray-
mond et al. our study sample did not reveal any difference
in the distribution of male and female patients concern-
ing systolic function (see table 1). An important difference
between the two studies concerned the definition of left
ventricular systolic dysfunction: Raymond et al. defined
left ventricular systolic dysfunction as EF<40%, so cases of
less severe left ventricular systolic dysfunction were
treated as unimpaired. It might be speculated, that this
caused the different results.
Heidenreich et al. concluded that screening with BNP fol-
lowed by echocardiography is economically attractive for
patient groups with at least a 1% prevalence of left ven-
tricular systolic dysfunction [23]. Our study confirmed a
4.3% prevalence for left ventricular systolic dysfunction in
a primary care setting using echocardiography. Therefore,
NT-proBNP assessment (which has the same assay costs as
BNP) would have been highly cost-effective. Irrespective
of its diagnostic power as a screening instrument, how-
ever, the additional costs of natriuretic peptide testing is
not self-evidently justified by its test accuracy [24]. In our
study, the risk score derived from a logistic regression
model of easily acquired clinical information would have
been even more cost-effective than assessing NT-proBNP,
because all information is available without any addi-
tional examination [25]. Such a risk score solely based on
clinical information would offer every general practitioner
direct access to a diagnostic tool with a test accuracy as
excellent as NT-proBNP testing. The multivariate logistic
regression analysis revealed three easily established fac-
tors as significant covariates. Since risk factors seldom
occur in isolation, modelling a risk score by using a set of
established risk factors is essential [26]. High values of
NT-pro BNP predict mortality even better than the pres-
ence of left ventricular systolic dysfunction does [27].
However, treatment with ACE inhibitors is recommended
for patients with left ventricular systolic dysfunction but
not for patients with isolated elevated levels of NT-pro
BNP.
Given the hypothesis that all patients of our study had
been considered for echocardiography, the clinical risk
score would have reduced the number of referrals to
echocardiography from 542 (all cases) to 210 (cases
where left ventricular systolic dysfunction could not be
ruled out), with 21 true positives and 189 false positives.
That means, 93 more cases could have been ruled out with
the clinical risk score than with NT-proBNP assessment,
which would have reduced the number of referrals from
542 to 303, with 21 true positives and 282 false positives.
Conclusion
According to our comparison, an evaluation of clinical
information could be at least as effective as NT-proBNP
testing in ruling out left ventricular systolic dysfunction in
primary care patients at risk. Therefore, general practition-
ers should be encouraged to rely on the diagnostic power
of the clinical information their patients provide.
Competing interests
Roche Diagnostics (Professor G. Hess, Mannheim, Ger-
many) was an official member of the study group and
supported the present investigation with NT-proBNP test
kits. There are no other competing interests.
Table 4: Results of classification of patients with impaired left ventricular function by NT-proBNP and risk score at cut-off points with 
high sensitivity and moderate specificity.
NT-proBNP correct classification NT-proBNP false classification
Risk score correct classification 203 148
Risk score false classification 55 136
McNemar test: p < 0.001.BMC Family Practice 2008, 9:14 http://www.biomedcentral.com/1471-2296/9/14
Page 7 of 7
(page number not for citation purposes)
Authors' contributions
JK and MS performed statistical analyses, wrote and edited
the manuscript; DW recruited the patients and coordinated
the study; CL, SK, and RW performed the clinical and
echocardiographic assessment; CP supervised the measure-
ment of the NT-proBNP levels; MMK, CHL, BP, and LB led
conception and design; all authors have contributed to the
conception and design and revised the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
We thank all patients who participated in this study for their cooperation. 
The technical assistance of Sabine Laurenzano is gratefully acknowledged. We 
gratefully acknowledge Prof. Wolfgang Himmel, Department of General 
Practice, University of Göttingen for his helpful comments on the manuscript. 
The study was supported by a grant from the German Ministry of Education 
and Research (01GK0201). Roche Diagnostics (Professor G. Hess, Man-
nheim, Germany) was an official member of the study group and supported 
the present investigation with NT-proBNP test kits (any influence on data 
analysis and publication was excluded). MS is funded by a Young Investigators' 
Award of the German Ministry of Education and Research BMBF (Grant Nr. 
01GK0516).
References
1. The SOLVD Investigators: Effect of enalapril on mortality and the
development of heart failure in asymptomatic patients with
reduced left ventricular ejection fractions.  N Engl J Med 1992,
327:685-91.
2. Badgett RG, Lucey CR, Mulrow CD: Can the clinical examination
diagnose left-sided heart failure in adults?  JAMA 1997,
277:1712-9.
3. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats
TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS,
Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams
CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs
AK, Nishimura R, Ornato JP, Page RL, Riegel B, American College of
Cardiology; American Heart Association Task Force on Practice
Guidelines; American College of Chest Physicians; International Society
for Heart and Lung Transplantation; Heart Rhythm Society: ACC/
AHA 2005 guideline update for the diagnosis and manage-
ment of chronic heart failure in the adult: a report of the
American College of Cardiology/American Heart Association
Task Force on Practice Guidelines (writing committee to
update the 2001 guidelines for the evaluation and manage-
ment of heart failure).  Circulation 2005, 112:e154-e235.
4. Hobbs FDR, Jones MI, Allan TF, Wilson S, Tobias R: European survey
of primary care physician perceptions on heart failure diagno-
sis and management (EURO-HF).  Eur Heart J 2000, 21:1877-87.
5. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ: Retrospective
analysis of the cost-effectiveness of using plasma brain natriu-
retic peptide in screening for left ventricular systolic dysfunc-
tion in the general population.  JACC 2003, 41:113-20.
6. Groenning BA, Raymond I, Hildebrandt JC, Nilsson JC, Baumann M,
Pedersen F: Diagnostic and prognostic evaluation of left ven-
tricular systolic heart failure by plasma N-terminal pro-brain
natriuretic peptide concentrations in a large sample of the
general population.  Heart 2004, 90:297-303.
7. Gustafsson F, Steensgaard-Hansen F, Badskjaer J, Poulsen AH, Corell P,
Hildebrandt P: Diagnostic and prognostic performance of NT-
terminal proBNP in primary care patients with suspected
heart failure.  J Card Fail 2005, 11:S15-S20.
8. Hobbs FDR, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre AK:
Reliability of N-terminal pro-brain natriuretic peptide assay in
diagnosis of heart failure. cohort study in representative and
high risk community populations.  BMJ 2002, 324:1-5.
9. McClure SJ, Caruana L, Davie AP, Goldthorp S, McMurray JJV: Cohort
study of plasma natriuretic peptides for identifying left ven-
tricular systolic dysfunction in primary care.  BMJ 1998,
317:516-9.
10. Lubien E, DeMaria A, Krishnaswamy P, Clopton P, Koon J, Kazanegra
R, Gardetto N, Wanner E, Maisel AS: Utility of B-natriuretic pep-
tide in detecting diastolic dysfunction. Comparison with Dop-
pler velocity recordings.  Circulation 2002, 105:595-601.
11. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PWF,
Levy D: Profile for estimating risk of heart failure.  Arch Intern
Med 1999, 159:1197-204.
12. Hanley JA, McNeil BJ: A method of comparing the areas under
receiver operating characteristic curves derived from the
same cases.  Radiology 1983, 148:839-43.
13. Sackett DL, Haynes RB: The architecture of diagnostic research.
BMJ 2002, 324:539-41.
14. Pewsner D, Battaglia M, Minder C, Marx H, Bucher HC, Egger M: Rul-
ing a diagnosis in or out with "SpPIn" and "SnNOut": a note
of caution.  BMJ 2004, 329:209-13.
15. Battaglia M, Pewsner D, Jüni P, Egger M, Bucher HC, Bachmann LM:
Accuracy of B-type natriuretic peptide tests to exclude con-
gestive heart failure. Systematic review of test accuracy stud-
ies.  Arch Intern Med 2006, 166:1073-80.
16. Doust JA, Glasziou P, Pietrzak E, Dobsen A: A systematic review of
the diagnostic accuracy of natriuretic peptides for heart fail-
ure.  Arch Intern 2004, 164(18):1978-1984.
17. Cowie MR: Estimating prognosis in heart failure: time for a bet-
ter approach.  Heart 2003, 89:587-8.
18. Caruana L, Petrie MC, McMurray JJV: Do patients with suspected
heart failure and preserved left ventricular systolic function
suffer from "diastolic heart failure" or from misdiagnosis? A
prospective descriptive study.  BMJ 2000, 321:215-8.
19. Petrie MC, Hogg K, Caruana L, McMurray JJV: Poor concordance of
commonly used echocardiographic measures of left ventricu-
lar diastolic dysfunction in patients with suspected heart fail-
ure but preserved systolic function: is there a reliable
echocardiographic measure of diastolic dysfunction?  Heart
2004, 90:511-7.
20. Nielsen OW, Hansen JF, Hilden J, Larsen CT, Svanegaard J: Risk
assessment of left ventricularsystolic dysfunction in primary
care: cross sectional study evaluating a range of diagnostic
tests.  BMJ 2000, 320:220-4.
21. Raymond I, Pedersen F, Steensgaard-Hansen F, Green A, Busch-
Sorensen M, Tuxen C, Appel J, Jacobsen J, Atar D, Hildebrandt P: Prev-
alence of impaired left ventricular systolic function and heart
failure in a middle aged and elderly urban population segment
of Copenhagen.  Heart 2003, 89:1422-9.
22. Pewsner D, Jüni P, Egger M, Battaglia M, Sundström J, Bachmann LM:
Accuracy of electrocardiography in diagnosis of left ventricu-
lar hypertrophy in arterial hypertension: systematic review.
BMJ 2007, 335:711.
23. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson
LW, Shekelle PG: Cost-effectiveness of screening with B-type
natriuretic peptide to identify patients with reduced left ven-
tricular ejection fraction.  JACC 2004, 43:1019-26.
24. Davenport C, Cheng EY, Kwok YT, Lai AH, Wakabayashi T, Hyde C,
Connock M: Assessing the diagnostic test accuracy of natriu-
retic peptides and ECG in the diagnosis of left ventricular
systolic dysfunction: a systematic review and meta-analysis.  Br
J Gen Pract 2006, 56:48-56.
25. Landray MJ, Lehman R, Arnold I: Measuring brain natriuretic pep-
tide in suspected left ventricular systolic dysfunction in gen-
eral practice: cross-sectional study.  BMJ 2000, 320:985-6.
26. Kannel WB, D'Agostino RB, Sullivan L, Wilson PWF: Concept and
usefulness of cardiovascular risk profiles.  Am Heart J 2004,
148:16-26.
27. Rutten JH, Boomsma F, Van den Meiracker AH: Diagnostic and
prognostic value of B-type natriuretic peptides in heart failure
or signs of heart failure.  Ned Tijdschr Geneeskd 2007, 151:2553-7.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2296/9/14/prepub